Development of a Phage Display Panning Strategy Utilizing Crude Antigens: Isolation of MERS-CoV Nucleoprotein human antibodies

Lim, Chia Chiu; Woo, Patrick C. Y.; Lim, Theam Soon

doi:10.1038/s41598-019-42628-6

Cited by 27 publications

(18 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A large phage-displayed human naive scFv library (Mehta I/II) with 2.7 × 10 10 clones from the Dana-Farber Cancer Institute was used as a resource for the isolation of human antibodies against MERS-CoV [135]. In another project, a research group in Malaysia improved panning strategies with a naïve human scFv library (library size of 10 9 ) to successfully identify mAbs specific to the MERS-CoV nucleoprotein [136].…”

Section: Methodologies For Developing Therapeutic Antibodiesmentioning

confidence: 99%

Development of therapeutic antibodies for the treatment of diseases

et al. 2020

View full text Add to dashboard Cite

It has been more than three decades since the first monoclonal antibody was approved by the United States Food and Drug Administration (US FDA) in 1986, and during this time, antibody engineering has dramatically evolved. Current antibody drugs have increasingly fewer adverse effects due to their high specificity. As a result, therapeutic antibodies have become the predominant class of new drugs developed in recent years. Over the past five years, antibodies have become the best-selling drugs in the pharmaceutical market, and in 2018, eight of the top ten bestselling drugs worldwide were biologics. The global therapeutic monoclonal antibody market was valued at approximately US$115.2 billion in 2018 and is expected to generate revenue of $150 billion by the end of 2019 and $300 billion by 2025. Thus, the market for therapeutic antibody drugs has experienced explosive growth as new drugs have been approved for treating various human diseases, including many cancers, autoimmune, metabolic and infectious diseases. As of December 2019, 79 therapeutic mAbs have been approved by the US FDA, but there is still significant growth potential. This review summarizes the latest market trends and outlines the preeminent antibody engineering technologies used in the development of therapeutic antibody drugs, such as humanization of monoclonal antibodies, phage display, the human antibody mouse, single B cell antibody technology, and affinity maturation. Finally, future applications and perspectives are also discussed.

show abstract

Section: Methodologies For Developing Therapeutic Antibodiesmentioning

confidence: 99%

Development of therapeutic antibodies for the treatment of diseases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Phage display technique of producing antibodies was developed for MERS-CoV and effectively applied in light of the fact that bacteriophages have the potential to produce recombinant antibodies (Ab) rapidly [12]. Another Yin-Yang biopanning technique features the chance of utilizing crude antigens for the isolation of monoclonal Ab by phage display method [13]. Before using these expensive techniques, production of artificial Ab was primarily done by using animals but it is a slow process and less cost effective than using bacteriophage display techniques [14].…”

Section: Early Studies Of Phage Therapy (Pt)mentioning

confidence: 99%

Role of Phage Therapy in COVID-19 Infection: Future Prospects

Singh¹,

Gaur²,

Kumar³

2021

Bacteriophages in Therapeutics

View full text Add to dashboard Cite

The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan City, China, in 2019. After that, the outbreak has grown into a global pandemic and definite treatment for the disease, termed coronavirus disease 2019 (COVID-19), is currently unavailable. The slow translational progress in the field of research suggests that a large number of studies are urgently required for targeted therapy. In this context, this hypothesis explores the role of bacteriophages on SARS-CoV-2, especially concerning phage therapy (PT). Several studies have confirmed that in addition to their antibacterial abilities, phages also show antiviral properties. It has also been shown that PT is effective for building immunity against viral pathogens by reducing the activation of NF kappa B; additionally, phages produce the antiviral protein phagicin. Phages can also induce antiviral immunity by upregulating expression of defensin 2. Phages may protect eukaryotic cells by competing with viral adsorption and viral penetration of cells, virus mediated cell apoptosis as well as replication. Moreover, by inhibiting activation of NF-κB and ROS production, phages can down regulate excessive inflammatory reactions relevant in clinical course of COVID-19. In this chapter, we hypothesize that the PT may play a therapeutic role in the treatment of COVID-19.

show abstract

“…They successfully displayed antibody variable regions on phages by using immunoglobulin variable genes of hybridomas and B cells. Since then, phage display technology has been extensively used for the discovery of antibodies or peptides against a large variety of antigens in many fields of application such as toxiconology (Ledsgaard et al, 2018), drug discovery (Erdag et al, 2007;Mimmi et al, 2019), immunization (Bahadır et al, 2011), epitope mapping (Folgori et al, 1994) and virus or toxin neutralization (Lim et al, 2019) by using phage peptide and antibody libraries.…”

Section: Phage Display Technologymentioning

confidence: 99%

SARS-CoV-2 neutralizing antibody development strategies

Balcıoğlu¹,

Öncü²,

Öztürk³

et al. 2020

Turk J Biol

View full text Add to dashboard Cite

In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The World Health Organization (WHO) described the most recent coronavirus epidemic as a global pandemic in March 2020. The virus spread triggered a health crisis (the COVID-19 disease) within three months, with socioeconomic implications. No approved targetedtherapies are available for COVID-19, yet. However, it is foreseen that antibody-based treatments may provide an immediate cure for patients. Current neutralizing antibody development studies primarily target the S protein among the structural elements of SARS-CoV-2, which mediates the cell entry of the virus through the angiotensin converting enzyme 2 (ACE2) receptor of host cells. This review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization assays.

show abstract

Development of a Phage Display Panning Strategy Utilizing Crude Antigens: Isolation of MERS-CoV Nucleoprotein human antibodies

Cited by 27 publications

References 69 publications

Development of therapeutic antibodies for the treatment of diseases

Development of therapeutic antibodies for the treatment of diseases

Role of Phage Therapy in COVID-19 Infection: Future Prospects

SARS-CoV-2 neutralizing antibody development strategies

Contact Info

Product

Resources

About